A phase II trial of personalized peptide vaccination in castration-resistant prostate cancer patients: prolongation of prostate-specific antigen doubling time-Reference-Cited by-同舟云学术

A phase II trial of personalized peptide vaccination in castration-resistant prostate cancer patients: prolongation of prostate-specific antigen doubling time

Published:2013-12 Issue:1 Volume:13 Page:
ISSN:1471-2407
Container-title:BMC Cancer
language:en
Short-container-title:BMC Cancer

Author:

Noguchi Masanori,Moriya Fukuko,Suekane Shigetaka,Ohnishi Rei,Matsueda Satoko,Sasada Tetsuro,Yamada Akira,Itoh Kyogo

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Oncology

Link

http://link.springer.com/content/pdf/10.1186/1471-2407-13-613.pdf

Reference25 articles.

1. Vollmer RT, Dawson NA, Vogelzang NJ: The dynamics of prostate specific antigen in hormone refractory prostate carcinoma: an analysis of cancer and leukemia group B study 9181 of megestrol acetate. Cancer. 1998, 83: 1989-1994. 10.1002/(SICI)1097-0142(19981101)83:9<1989::AID-CNCR15>3.0.CO;2-V.

2. Armstrong AJ, Garrett-Mayer E, Ou Yang YC, Carducci MA, Tannock I, de Wit R, Eisenberger M: Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol. 2007, 25: 3965-3970. 10.1200/JCO.2007.11.4769.

3. Scher HI, Kelly WM, Zhang ZF, Ouyang P, Sun M, Schwartz M, Ding C, Wang W, Horak ID, Kremer AB: Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer. J Natl Cancer Inst. 1999, 91: 244-251. 10.1093/jnci/91.3.244.

4. Petrylak DP, Ankerst DP, Jiang CS, Tangen CM, Hussain MH, Lara PN, Jones JA, Taplin ME, Burch PA, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED: Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99–16. Natl Cancer Inst. 2006, 98: 516-521. 10.1093/jnci/djj129.

5. Hoos A, Eggermont AM, Janetzki S, Hodi FS, Ibrahim R, Anderson A, Humphrey R, Blumenstein B, Old L, Wolchok J: Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst. 2010, 102: 1388-1397. 10.1093/jnci/djq310.

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Potential of Personalized Dendritic Cell-Based Immunohybridoma Vaccines to Treat Prostate Cancer;Life;2023-07-01

2. Survival analysis of multiple peptide vaccination for the selection of correlated peptides in urological cancers;Cancer Science;2018-07-23

3. Clinical Variables Associated With Overall Survival in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Sipuleucel-T Immunotherapy;Clinical Genitourinary Cancer;2018-06

4. Immune-based therapies for metastatic prostate cancer: an update;Immunotherapy;2018-03-01

5. Immune Therapy for Castration-Resistant Prostate Cancer;Hormone Therapy and Castration Resistance of Prostate Cancer;2018